FDA Approves HCV Treatment Vosevi for Previously Treated Patients
July 19th 2017The FDA recently approved Vosevi-a fixed-dose combination tablet containing FDA-approved sofosbuvir and velpatasvir, and a new drug, voxilaprevi-to treat adults with the hepatitis C virus who do not have cirrhosis (liver disease).
Read More
CDC Finds Higher ALS, Parkinson Disease Mortality in Those With White-Collar Occupations
July 16th 2017The progressive neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and Parkinson disease share the risk factors of increased age and male sex, but new research indicates there is also an association between a patient’s occupation and the mortality rate from these diseases.
Read More
Investor Reactions to Orphan Drug Designation Strongest for Oncology Therapies, Study Finds
July 14th 2017A new study examines the impact that a pharmaceutical’s designation as an orphan drug can have on its manufacturer’s stock prices, and finds that the largest returns were for oncology drugs.
Read More
Novartis' CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory Panel
July 11th 2017Novartis’ chimeric antigen receptor T-cell (CAR-T) therapy for treating pediatric leukemia is on the cusp of being the first FDA-approved gene therapy, which will lead to new developments and utilizations of CAR-T therapy for treating other advanced blood cancers.
Read More
New Report Discusses Effective Care for High-Need Patients
July 11th 2017A new report by the National Academy of Medicine explores how the healthcare system can improve care and manage costs for the 5% of high-need patients who account for almost half of the healthcare spending in the United States.
Read More
Review Discusses Pneumonitis as an Adverse Effect of Checkpoint Inhibitors
July 10th 2017Research published by Cancer Management & Research explores the efficacy of treating multiple malignancies with immune checkpoint inhibitors and programmed cell death-1 inhibitors (PD-1). The review specifically analyzes the presence of pneumonitis as an adverse event following treatment of checkpoint inhibitors.
Read More
New Antibody Demonstrates 2-Pronged Approach in Treating Blood Cancer
July 9th 2017A study published by BloodAdvances, a Journal of the American Society of Hematology, demonstrated the potential of the 2-pronged approach in treating non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia.
Read More
Phase 2 Trial Results Suggest Luspatercept Is Effective in Treating Myelodysplastic Syndrome
July 7th 2017Treating myelodysplastic syndrome patients with luspatercept can increase hemoglobin and decrease the burden of red blood cell transfusion for more than 26 months, according to new results from a phase 2 trial.
Read More
Stanford Medicine's "Health Trends Report" Analyzes Big Data in Healthcare
July 6th 2017Stanford Medicine recently published its first annual Health Trends Report, revealing the prominence of big data and the potential difficulties it can produce when attempting to improve the healthcare system.
Read More